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Introduction {#sec1}
============

The use of photochemically activated compounds for labeling proteins and other biologically active molecules was introduced by Westheimer and co-workers in 1962 ([@bib35]). Since then, photoaffinity labeling (PAL) has matured, and a wide array of reagents are available for studying the structure and function of biological systems ([@bib1], [@bib5], [@bib21]). Photochemical activation offers a number of advantages over thermochemical processes. For instance, photoreactive groups can be selected whereby, (1) the reagent is stable under ambient conditions, (2) photoactivation occurs specifically at a wavelength that is not absorbed by the biological vector, and (3) the conjugation step involves a chemoselective reaction with the target molecule. Furthermore, because photochemical activation proceeds via an excited electronic state that generates extremely reactive intermediates like carbenes, nitrenes, and radicals, the rates of photochemical conjugation reactions can be several orders of magnitude faster than those of standard methods ([@bib6], [@bib10], [@bib19], [@bib32]). High reactivity of the photo-induced intermediates presents both advantages and disadvantages. One of the benefits is that photoactive reagents can yield high labeling efficiencies in short reaction times. However, to achieve efficient conjugation, PAL methods often rely on a mechanism in which the photoactive reagent and the target protein form a non-covalent pre-association complex. Pre-association facilitates pseudo-first-order intramolecular bond formation and minimizes the probability of quenching by background media (i.e., by the solvent, oxygen, salts, etc.). However, the problem with this approach is that it restricts most PAL tools to systems that self-assemble.

From the radiochemistry perspective, photochemical reactions are an attractive platform for developing radiotracers. For molecules that undergo radioactive decay, chemical kinetics is one of the main factors in determining if a reaction is suitable for use in radiotracer synthesis ([@bib13]). As photochemical reactions often proceed with rate constants that tend toward the rate of diffusion, combining photochemistry with radiochemistry (*photoradiochemistry*) is a logical step.

Several groups have reported the use of photochemical reactions in the synthesis of radiolabeled compounds ([@bib12], [@bib22], [@bib23], [@bib24], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib33], [@bib36], [@bib37], [@bib38], [@bib42]). However, it is surprising that to date, photochemistry has had minimal impact on radiopharmaceutical science. The main bottlenecks to a more widespread use of photoradiochemistry for labeling proteins, peptides, and small molecules are (1) avoiding the need to form a pre-associated complex, (2) controlling chemoselectivity in the presence of competing nucleophiles, and (3) ensuring that the rate of productive *bimolecular* conjugation exceeds that of background quenching reactions. If a photochemical process can be tuned to favor bimolecular coupling, then photoradiochemistry may become a more general tool in radiotracer synthesis.

A specific area for potential applications of photoradiochemistry is the synthesis of radiolabeled monoclonal antibodies (mAbs) or immunoglobulin fragments for use in positron emission tomography (immuno-PET) and radioimmunotherapy ([@bib3]). Zirconium-89 (*t*~1/2~ = 78.41 h) has emerged as the radionuclide of choice for immuno-PET. In almost all available methods for radiolabeling mAbs, the production of ^89^Zr-mAbs relies on a two-step procedure ([Scheme 1](#sch1){ref-type="fig"}). Initially, the antibody is purified from a source and then functionalized with a suitable metal-ion-binding chelate. For ^89^Zr, the chelate of choice is usually a derivative of desferrioxamine B (DFO), but a number of alternative chelates have been reported ([@bib3]). After conjugation, the functionalized mAb is re-purified, characterized, and stored before radiolabeling. Although this two-step approach is highly successful, there are several drawbacks. First, the conjugation chemistry is time consuming and may involve multiple chemical transformations that risk compromising the biological integrity of the mAb. Second, for applications in the clinic, the conjugation chemistry should ideally be performed in accordance with current Good Manufacturing Practice. Third, the conjugated mAb is a new molecular entity, which may be subject to stringent testing, including expensive toxicological test. Finally, storage of the radiolabeling precursor raises concerns over the long-term chemical and biochemical stability.Scheme 1Mechanistic Routes toward Radiolabeled Antibodies and Other Proteins

We postulated that photoradiochemistry could be used to streamline the production of radiolabeled mAbs (and other radiolabeled proteins or peptides) by simplifying the procedure to a one-pot reaction and eliminating the need to isolate or store the functionalized intermediate. Two mechanistically distinct processes can be envisaged for a one-pot procedure: a two-step pre-radiolabeling approach and a one-step pathway in which the radiolabeling and photochemical conjugation reactions occur simultaneously. Here, we present detailed experimental and theoretical data evaluating the photoradiochemical synthesis of ^89^Zr-labeled trastuzumab.

Results and Discussion {#sec2}
======================

Our initial proof-of-concept studies found that the macrocyclic chelate, (2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), when functionalized with a photoreactive arylazide (ArN~3~) facilitated a two-step photoradiolabeling of trastuzumab with ^68^Ga^3+^ ions ([@bib8], [@bib31]). Although technically feasible, the combination of short-lived ^68^Ga (*t*~1/2~ = 67.71 min) with mAbs (∼150 kDa) is not ideal because of the mismatch between the timescales of radioactive decay and radiotracer pharmacokinetics *in vivo*. In addition, ^68^Ga^3+^ radiochemistry usually requires acidic media (to avoid hydrolysis of the metal ion), which is suboptimal for photochemical conjugation using the ArN~3~ group ([@bib2], [@bib9], [@bib10], [@bib11]). Here, we focused our efforts on developing a photoradiochemical process for producing ^89^Zr-labeled mAbs. Zirconium-89 radiochemistry normally starts from the zirconium tetraoxalate anion, \[^89^Zr\]\[Zr(C~2~O~4~)~4~\]^4--^(aq.), and complexation by DFO derivatives can be accomplished over a wide pH range (from approximately pH 5--10, with optimal yields attained by using pH 6--8.5) ([@bib14], [@bib41]). Thus ^89^Zr-radiochemistry is not only ideal for immuno-PET but also facilitates simultaneous photoradiolabeling.

Chemical and Radiochemical Synthesis {#sec2.1}
------------------------------------

The photoactive chelate DFO-ArN~3~ (**1**) was synthesized by using standard chemical transformations ([Scheme 2](#sch2){ref-type="fig"}). The compound was isolated in high purity by semi-preparative high-performance liquid chromatography and characterized by ultrahigh-performance liquid chromatography (UHPLC), high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), one- and two-dimensional ^1^H and ^13^C nuclear magnetic resonance spectroscopies, and electronic absorption spectroscopy ([Transparent Methods Figures S2--S8](#mmc1){ref-type="supplementary-material"}).Scheme 2Chemical Synthesis of DFO-ArN~3~ (**1**) and Complexation of Zr^4+^ Ions to Give the Non-radioactive (Zr-**1**^**+**^) and Radiolabeled ^89^Zr-**1**^**+**^) Coordination Complexes

The non-radioactive complex, \[ZrDFO-ArN~3~\]^+^ (Zr-**1**^**+**^), was prepared by the reaction of compound **1** with ZrCl~4~(aq.), and characterized by HR-ESI-MS and UHPLC ([Figure 1](#fig1){ref-type="fig"} and [Transparent Methods Figures S9](#mmc1){ref-type="supplementary-material"} and [S10](#mmc1){ref-type="supplementary-material"}). The radiolabeled complex \[^89^Zr\]\[ZrDFO-ArN~3~\]^+^ (^89^Zr-**1**^**+**^) was prepared as a single radioactive species, the identity of which was confirmed by comparison of retention times with the authenticated non-radioactive sample and by standard co-injection methods ([Figure 1](#fig1){ref-type="fig"}, blue radiotrace).Figure 1Radioactive UHPLC Characterization DataUHPLC chromatograms showing quantitative radiolabeling to give \[^89^Zr\]\[ZrDFO-ArN~3~\]^+^ (^89^Zr-**1**^**+**^, blue trace, RCP \>99%, RCC \>99%) and electronic absorption chromatograms measured at 220 nm (green), 254 nm (red), and 280 nm (black) showing co-elution with an authenticated sample of non-radioactive Zr-**1**^**+**^.

Photochemical Kinetics {#sec2.2}
----------------------

After confirming that ^89^Zr-**1**^**+**^ could be prepared via standard radiolabeling methods, the photochemical activity of compound **1** was tested under irradiation with UV light. Three separate light sources were tested including two variable-intensity light-emitting diodes (LEDs) with peak emission wavelengths at ∼365 nm and ∼395 nm and a high-powered Rayonet reactor ([Transparent Methods Figure S1](#mmc1){ref-type="supplementary-material"}). The photochemical degradation kinetics of compound **1**, induced by using variable light intensities, was monitored by UHPLC ([Figure 2](#fig2){ref-type="fig"} and [Transparent Methods Table S2](#mmc1){ref-type="supplementary-material"}). Experiments confirmed that compound **1** was photoactive. All peaks in the UHPLC associated with photodegraded products were found to be more hydrophilic than the parent compound, which is consistent with the established mechanism of ArN~3~ activation in aqueous media ([@bib19]). After light absorption, ArN~3~ releases N~2~(g) and forms a short-lived arylnitrene species in the singlet (^1^A~2~) ground state ([@bib10]). This arylnitrene undergoes rapid intramolecular rearrangement to give benzazirine or ketenimine intermediates ([@bib32]). When powerful nucleophiles are present, the ketenimine species reacts to form more polar azepine adducts. In the absence of nucleophiles, hydrolysis reactions can form the 3*H*-azepin-2-ol or the 1,3-dihydro-2*H*-azepin-2-one tautomers ([@bib4]). Photo-irradiated samples of compound **1** showed that at least six new species formed ([Figure 2](#fig2){ref-type="fig"}A). This observation is consistent with the mechanism of activation. The DFO ligand contains several nucleophilic groups (hydroxamates) that can induce intramolecular reactions with the ketenimine intermediate forming various cycles.Figure 2Kinetic Data on the Photochemically Induced Degradation of Compound **1** during Irradiation with UV Light (365 nm)(A) Normalized UHPLC chromatograms recorded between 0 and 25 min (50% LED power). \* Indicates starting material (compound **1**).(B) Kinetic plot showing the change in concentration of compound **1** versus irradiation time (min.) using different LED intensities. Note, data are fitted with a first-order decay (*R*^2^ \>0.999 for each dataset), and the observed first-order rate constants, *k*~obs~/min^−1^, are shown in the inset. Error bars correspond to one standard deviation.(C) Plot of the normalized observed rate constant versus the normalized LED intensity confirming that photodegradation is first order (gradient ∼1.0) with respect to light intensity.

By integrating the peak in the UHPLC associated with compound **1**, it was possible to measure the photochemical degradation kinetics ([Figure 2](#fig2){ref-type="fig"}B). At room temperature, and using the LED (365 nm) at different intensities (25%, 50%, and 100%), the photochemical degradation of compound **1** fitted a first-order kinetic scheme (non-linear regression coefficient, *R*^2^ \>0.999 at each light intensity). Changes in the observed rate constant, *k*~obs~/min^−1^, were found to be linearly dependent on the light intensity ([Figure 2](#fig2){ref-type="fig"}C). These data are consistent with the anticipated photochemical response of molecules containing ArN~3~ groups ([@bib10], [@bib11], [@bib19]).

Quantum Yield of Photochemical Activation {#sec2.3}
-----------------------------------------

How efficient is photochemical activation of the ArN~3~ in compound **1**? This question can be answered by determining the photochemical quantum yield (Φ), which is defined as the ratio of the number of reactions (*n*~r~) to the number of photons absorbed (*n*~abs~, [Equation 1](#fd1){ref-type="disp-formula"}) ([@bib19])$$\text{Φ} = \frac{n_{\text{r}}}{n_{\text{abs}}}$$

An expression for the number of reactions at time *t* is given by the change in concentration (*c*) of the starting material multiplied by the volume (*V*, [Equation 2](#fd2){ref-type="disp-formula"}).$$n_{\text{r}}\left( t \right) = \left( {c_{0} - c\left( t \right)} \right) \cdot V$$

The molar photon flux $q_{m,\gamma}^{0}$ is defined as the number of photons in moles (i.e., in units of Einstein) incident on a sample per unit time and can be expressed as the light power ($P_{m,\gamma}^{0}$) divided by the product of Avogadro\'s constant (*N*~A~) and the energy of each photon ($h\nu$) as given by [Equation 3](#fd3){ref-type="disp-formula"}.$$q_{m,\gamma}^{0} = \frac{P_{m,\gamma}^{0}}{N_{\text{A}} \cdot h\nu}$$

The fraction of photons absorbed can be expressed as 1 minus the transmittance (*T*), which can be substituted for the measured absorbance using the Beer-Lambert law ([Equation 4](#fd4){ref-type="disp-formula"}).$$T\left( t \right) = 10^{- A{(t)}},\ \ \ \text{where~~~}A\left( t \right) = \ ɛ_{\lambda}\ c\left( t \right)\ d$$

The differential photon absorption ($dn_{\gamma}\left( t \right)$) at a given time and wavelength (*λ*) can be calculated by [Equation 5](#fd5){ref-type="disp-formula"}.$$dn_{\text{abs}}\left( t \right) = q_{m,\lambda}^{0}\left\lbrack {1 - 10^{- A{(t)}}} \right\rbrack dt$$

Finally, it follows that the quantum yield is given by [Equation 6](#fd6){ref-type="disp-formula"}.$$\text{Φ} = \frac{\left( {c_{0} - c\left( t \right)} \right) \cdot V}{\int_{0}^{t}{q_{m,\lambda}^{0}\left\lbrack {1 - 10^{- A{(t)}}} \right\rbrack dt}}$$

Using experimental values from the kinetics of photochemical degradation of compound **1**, a photochemical quantum yield of 4.35% ± 0.43% was calculated. This means that around one in every ∼23 photons that is absorbed (at ∼365 nm) leads to photochemical activation via loss of N~2~ as opposed to relaxation through other radiative or non-radiative (chemical quenching) pathways. These data indicated that photochemical activation of compound **1**, and other molecules functionalized with the ArN~3~ group, is a highly efficient process.

Density Functional Theory Calculations {#sec2.4}
--------------------------------------

Next, to understand the thermochemical stability and photochemical reactivity of compound **1** in more detail, density functional theory (DFT) calculations were performed. The acyclic nature of compound **1** means that the compound has a large degree of conformational freedom. Therefore, to simplify calculation of the reaction coordinate and the electronic excitation profile, the non-substituted arylazide (benzylazide) was used as a model compound. All calculations used the uB3LYP/6-311++G(d,p) level of theory and included a polarizable continuum model (PCM, water). The calculated reaction coordinate is shown in [Figure 3](#fig3){ref-type="fig"}. Relative changes in the reaction free energy, Δ*G*; enthalpy, Δ*H*; and entropy Δ*S* of each species, including all transition states between the arylazide starting material and the most stable geometric isomer formed (*cis*-*N*-methyl-3*H*-azepin-2-amine) after addition of methylamine to the ketenimine intermediate, are shown. In addition, relative energies of the possible electronic states of the arylnitrene were calculated.Figure 3DFT-Calculated (uB3LYP/6-311++G(d,p)/PCM) Reaction CoordinateThe relative calculated differences in free energy (Δ*G*/kJ mol^−1^), enthalpy (Δ*H*/kJ mol^−1^), and entropy (Δ*S*/J K^−1^ mol^−1^, at 298.15 K) of the various intermediates and transition states that connect arylazide (PhN~3~) with the *N*-methyl-*cis*-azepin-2-amine product are shown. Photochemically induced reactivity of arylazides proceeds via the ground-state open-shell singlet nitrene (^1^A~2~ state) corresponding to the (*p*~x~)^1^(*p*~y~)^1^ electronic configuration where the *p*y orbital on the N atom lies in the plane of the C~6~H~5~ ring. Note, owing to spin contamination, the energy of the ^1^A~2~ state was estimated using the sum method by Ziegler et al. ([@bib43]).

The first feature to note is that formation of transition state 1 (TS1), which corresponds to loss of N~2~ from arylazide, has a calculated free energy barrier of 143 kJ mol^−1^ in solution phase. This high barrier accounts for the thermal stability of the ArN~3~ group and contributes to the prolonged shelf-life of chelates (like compound **1**) that are derivatized with ArN~3~. Irradiation with UV light can circumvent this thermodynamic barrier (see the time-dependent DFT \[TD-DFT)\] section below) and leads to the formation of arylnitrene in the lowest energy open-shell singlet state (^1^A~2~). The ^1^A~2~ ground state has a formal electronic configuration of (*p*~x~)^1^(*p*~y~)^1^ where the two unpaired electrons are primarily located in the *p*-orbitals of the nitrogen atom with some delocalization to the aromatic ring. Formation of the more stable triplet state (^3^A~2~) is spin forbidden, and the two closed-shell singlet states (both ^1^A~1~ with either (*p*~x~)^2^ or (*p*~y~)^2^ electronic configurations centered on the N atom) are calculated to be higher in energy, with a low probability of populating these states at ambient temperature. The TS2 corresponding to the intramolecular rearrangement of arylnitrene has a calculated barrier of only ΔΔ*G*~TS2~ = 54 kJ mol^−1^, which includes destabilization from the loss of aromaticity. After ring insertion occurs, the benzazirine species (Δ*G* = 22 kJ mol^−1^) isomerizes to give the more stable ketenimine intermediate (Δ*G* = −3 kJ mol^−1^) via a relatively low-energy TS3 (Δ*G* = 37 kJ mol^−1^). Nucleophilic attack by methylamine (CH~3~NH~2~) at the 2-position of the ketenimine intermediate proceeds via TS4 (Δ*G* = 51 kJ mol^−1^) and initially produces the NH-azepin adduct. This NH-azepin then isomerizes to yield the *cis*-azepin-2-amine product. Formation of the azepin-2-amine from benzylazide and methylamine is calculated to be thermodynamically spontaneous with an overall reaction free energy of Δ*G* = −166 kJ mol^−1^. As expected, the main driving force for the initial photoactivation is entropic (N~2~(g) release, Δ*S* = +137 J^−1^ K^−1^ mol^−1^). However, nucleophilic addition to the ketenimine, and similarly, conjugation of a photoactive chelate to a biologically active molecule, is driven primarily by changes in enthalpy (Δ*H* = −173 kJ mol^−1^).

TD-DFT calculations were used to probe the electronic nature of the photoactivation of arylazide. An overlay of the experimentally measured electronic absorption spectrum of compound **1** (in MeOH) and the TD-DFT-calculated spectrum is presented in [Figure 4](#fig4){ref-type="fig"} (see also [Transparent Methods Figure S8](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}). Perhaps surprisingly, compound **1**, and indeed arylazide compounds like 4-azidobenzoic acid show almost no absorbance at wavelengths above ∼325 nm. Measurements of the molar absorption coefficients at 365 and 395 nm gave values of 16.9 ± 1.9 M^−1^ cm^−1^ and 5.2 ± 1.3 M^−1^ cm^−1^, respectively. Nevertheless, TD-DFT calculations of the 16 lowest energy excited states (including both singlets and triplets) of arylazide confirmed that excitation bands are present in the wavelength range used to promote the photochemistry. Electronic transitions to six major singlet excited states (assigned as bands A to F) contribute to the measured absorption profile of compound **1** in the region 200--600 nm. Note that at shorter wavelengths, the fit between the calculated and the experimental spectrum is less accurate because of the use of the model arylazide and the continuum solvation model, which do not account for the full electronic complexity or solvation dynamics of compound **1**. However, experimental features associated with absorption at wavelengths \>250 nm are well reproduced.Figure 4Experimental Electronic Absorption Spectroscopy and Time-Dependent DFTOverlay of the experimentally measured electronic absorption spectrum of compound **1** and the TD-DFT (uB3LYP/6-311++G(d,p)/PCM)-calculated spectrum of the model compound arylazide (PhN~3~). Note that the calculated spectrum was produced by using Lorentzian broadening, 20-nm full-width at half maximum. Calculated energies and oscillator strengths (*f*/a.u.) of the bands corresponding to transitions to the first six excited singlet states with non-zero expectation values are shown by vertical red lines (band details inset). For reference, band energies to the excited triplet states are shown by vertical green lines. The simulated spectrum and all calculated energies are *x*-shifted by +12 nm for clarity. Molecular orbital contributions involved in the excitation to the main singlet bands are presented in [Table S1](#mmc1){ref-type="supplementary-material"}.

TD-DFT calculations allow deconvolution of the change in the electronic density associated with the formation of a particular excited state in terms of electronic mixing between the ground-state molecular orbitals (MOs) ([Figure 5](#fig5){ref-type="fig"}, and [Transparent Methods Table S1](#mmc1){ref-type="supplementary-material"}). MO analysis from TD-DFT calculations performed on benzylazide found that absorption band A (corresponding to excitation to the lowest energy excited singlet state) involves 96.4% mixing of the electron density from the highest occupied MO to the lowest unoccupied molecular orbital (LUMO). Inspection of the MO isosurfaces showed that this transition involves primarily transfer of electron density from a populated ππ\* orbital of the benzyl ring to the unoccupied, in-plane antibonding *p*π\* orbital centered on the azide group. Populating this excited state weakens the azide bond and stimulates N~2~ dissociation. Interestingly, our experimental observations indicate that any wavelength that populates the first excited singlet state can induce arylazide activation. However, test experiments using a shorter-wavelength LED (∼275 nm), which populates the second or third excited singlet states (bands B and C, respectively), found negligible photochemical activation of the ArN~3~ group (data not shown). This observation is consistent with the TD-DFT calculations, which indicate that bands B and C involve electronic transitions to higher-energy virtual orbitals (LUMO+1 and above). Kasha\'s rule suggests that relaxation of second and third excited singlet states of ArN~3~ should populate the LUMO, but inspection of the MOs shows that this process is symmetry forbidden ([Figure 5](#fig5){ref-type="fig"}).Figure 5Molecular Orbital Diagram of ArN~3~DFT-calculated (B3LYP/6-311++G(d,p)/PCM) molecular orbital diagram. Electron density isosurfaces of the three highest occupied molecular orbitals (HOMOs) and three lowest unoccupied molecular orbitals (LUMOs) for the model compound arylazide (PhN~3~) are shown. Note that the isosurfaces were generated by using a contour value of 0.035 and correspond to 96.5% of the total electron density.

Two-Step Photochemical Conjugation and ^89^Zr-Radiolabeling of Trastuzumab {#sec2.5}
--------------------------------------------------------------------------

Before investigating a simultaneous one-pot photoradiochemical process, experiments were performed using the traditional two-step approach. This route involved the photochemical conjugation between compound **1** and trastuzumab, followed by ^89^Zr-radiolabeling ([Scheme 3](#sch3){ref-type="fig"}, bottom pathway). The photochemical conjugation was performed at room temperature for 25 min using a Rayonet reactor. The DFO-azepin-trastuzumab conjugate was purified by using a combination of size exclusion chromatography (SEC) methods including spin column centrifugation and preparative PD-10 gel filtration. DFO-azepin-trastuzumab was then radiolabeled with ^89^Zr using standard conditions ([@bib15], [@bib16], [@bib17], [@bib34], [@bib39], [@bib40], [@bib41]). Aliquots of the crude radiolabeling mixture were retained, and then the product was purified and formulated in sterile PBS by using standard SEC methods. Analytical measurements on the crude and purified samples of \[^89^Zr\]ZrDFO-azepin-trastuzumab were performed using radioactive instant thin-layer chromatography (radio-iTLC), analytical PD-10-SEC, and radioactive SEC-UHPLC ([Figure 6](#fig6){ref-type="fig"}).Scheme 3Photoradiochemical Synthesis of \[^89^Zr\]ZrDFO-Azepin-Trastuzumab via Three Separate Routes(Top) Pre-radiolabelling and subsequent photochemical conjugation of \[^89^Zr\]ZrDFO-ArN~3~ (^89^Zr-**1**^**+**^) with the antibody. (Middle) Simultaneous one-step photoradiochemical labeling. (Bottom) Two-step photochemical conjugation of the antibody and subsequent ^89^Zr radiolabeling of the isolated DFO-azepin-trastuzumab intermediate.Figure 6Characterization Data for the Radiochemical Synthesis of \[^89^Zr\]ZrDFO-Azepin-Trastuzumab(A) Radio-iTLC chromatograms showing \[^89^Zr\]ZrEDTA control; the crude reaction mixture at 15, 40, and 60 min; and the purified product.(B and C) (B) Analytical PD-10-SEC elution profiles, and (C) SEC-UHPLC chromatograms of the crude and purified product.

Experiments confirmed that the DFO-azepin-trastuzumab was radiolabeled efficiently with ^89^Zr giving a crude radiochemical conversion (RCC) of \>98% after incubating the mixture at room temperature for 15 min. On scaling up the radiolabeling reaction for use in cellular and animal experiments, the final radiochemical yield (RCY) of the purified sample was \>99%, and the radiochemical purity (RCP) was measured at \>99.5% by analytical PD-10-SEC and \>98% by SEC-UHPLC. For the preparations used in the animal studies, the final activity concentration was 29.7 MBq mL^−1^, with a decay-corrected molar activity (*A*~m~) of 13.7 MBq nmol^−1^ of protein for the stock sample used in the normal doses (*vide infra*).

Further ^89^Zr-radiolabeling experiments were performed to measure the radiolabeling kinetics and overall RCC yields of DFO-azepin-trastuzumab samples that were prepared using different initial chelate-to-mAb ratios in the photochemical conjugation step ([Figure 7](#fig7){ref-type="fig"} and [Transparent Methods Figure S11](#mmc1){ref-type="supplementary-material"}). For each sample, the radiolabeling kinetics was monitored by radio-iTLC ([Figure 7](#fig7){ref-type="fig"}A) and the RCC (%) versus time was plotted ([Figure 7](#fig7){ref-type="fig"}B). These experiments showed a linear relation between the initial chelate-to-mAb ratio and the overall RCC at equilibrium (time points \>60 min, [Figure S11](#mmc1){ref-type="supplementary-material"}). Using these data, combined with the experimentally determined molar activity of the stock solution of \[^89^Zr\]\[Zr(C~2~O~4~)~4~\]^4--^ (measured by titration with DFO) ([@bib34]) the photochemical conjugation efficiency between DFO-ArN~3~ (**1**) and trastuzumab was estimated to be 3.5% ± 0.4% (*n* = 3). Hence, for the samples used in the biological studies, an initial chelate-to-mAb ratio of 26.4:1 yielded ∼0.85 accessible chelates per mAb in the final product.Figure 7\[^89^Zr\]ZrDFO-azepin-trastuzumab Radiolabeling Kinetics and Stability Data(A) Radio-iTLC chromatograms showing the kinetics of formation of \[^89^Zr\]ZrDFO-azepin-trastuzumab versus time using a pre-functionalized DFO-azepin-trastuzumab sample prepared with an initial chelate-to-mAb ratio of 26.4:1. Data for reactions starting with different initial chelate-to-mAb ratios are presented in [Figure S11](#mmc1){ref-type="supplementary-material"}.(B) Plot of the percentage radiochemical conversion (RCC) versus time using samples of DFO-azepin-trastuzumab pre-conjugated at different initial chelate-to-mAb ratios.(C) Radioactive SEC-UHPLC confirming that \[^89^Zr\]ZrDFO-azepin-trastuzumab remains stable with respect to change in radiochemical purity during incubation in human serum at 37°C for 92 h.

The radiochemical stability of \[^89^Zr\]ZrDFO-azepin-trastuzumab with respect to change in the RCP during incubation in human serum at 37°C for up to 92 h was determined by SEC-UHPLC ([Figure 7](#fig7){ref-type="fig"}C). Experiments confirmed that the ^89^Zr activity remained bound to the mAb (\<2% decrease in RCP after 92 h) with essentially no transchelation serum proteins (transferrin, albumin, etc.).

Cellular Saturation Binding Assays (Immunoreactivity) {#sec2.6}
-----------------------------------------------------

The biochemical viability of \[^89^Zr\]ZrDFO-azepin-trastuzumab was measured by using standard cellular saturation binding assays in accordance with the methods introduced by Lindmo et al.([@bib18], [@bib20], [@bib25]). The human ovarian cancer cell line SK-OV-3 shows high expression of the human epidermal growth factor receptor 2 (HER2/*neu*), which is the target protein of trastuzumab. Saturation binding experiments confirmed that the protein remained biochemically active with an estimated immunoreactivity fraction between 63% and 74% (*n* = 2, [Figure 8](#fig8){ref-type="fig"}). Note that these cellular assays were incubated for only 1 h and the slightly low value of the immunoreactivity is primarily associated with slow binding kinetics. Nevertheless, the immunoreactive fraction is comparable to the reported value of 87% ± 7% obtained with \[^89^Zr\]ZrDFO-Nsucc-trastuzumab that was conjugated using one of the standard thermochemical routes (*N*-succinyl activated ester) ([@bib16]).Figure 8Measurement of the Immunoreactive Fraction of \[^89^Zr\]ZrDFO-Azepin-Trastuzumab as Determined by Cellular Binding to SK-OV-3 (HER2/*neu* positive) Cells(A) Saturation binding plot. Error bars correspond to one standard deviation.(B) Lindmo plot.

Small-Animal PET Imaging and Biodistribution Studies {#sec2.7}
----------------------------------------------------

After confirming that \[^89^Zr\]ZrDFO-azepin-trastuzumab was chemically stable and biochemically active *in vitro*, the pharmacokinetics and target specificity were evaluated in athymic nude mice bearing subcutaneous SK-OV-3 tumors. PET images were recorded at multiple time points between 2 and 94 h post-administration. Two groups of mice were used. The normal group (*n* = 5) received a high molar activity formulation (13.7 MBq nmol^−1^), and the blocking group received the same amount of radioactivity but a reduced molar activity of 0.14 MBq nmol^−1^. Representative PET images showing coronal and axial planes taken through the center of the tumors are presented in [Figure 9](#fig9){ref-type="fig"} (see also [Transparent Methods Figures S12](#mmc1){ref-type="supplementary-material"} and [S13](#mmc1){ref-type="supplementary-material"}). PET imaging data were also quantified by drawing volumes-of-interest over various tissues and plotting the data as time-activity bar charts ([Figure 10](#fig10){ref-type="fig"}, based on quantification of the images in units of percentage injected dose per gram (%ID g^−1^), and [Figure S14](#mmc1){ref-type="supplementary-material"} for equivalent data using image quantification in units of the mean standardized uptake value). The pharmacokinetic profile and tumor uptake of \[^89^Zr\]ZrDFO-azepin-trastuzumab was consistent with previously reported experiments using ^89^Zr-DFO-radiolabeled trastuzumab produced via traditional coupling chemistries ([@bib16]).Figure 9Temporal \[^89^Zr\]ZrDFO-Azepin-Trastuzumab PET Images Recorded in Mice Bearing SK-OV-3 Tumors on the Right Flank T, tumor; H, heart; L, liver; Sp, spleenFigure 10Time-Activity Bar Chart Showing the Activity Associated with Different Tissues (volumes of Interest, VOI) versus TimeData presented are based on quantification of the PET images in units of %ID cm^−3^. Equivalent data using quantification of the PET images in terms of the mean standardized uptake value are shown in [Figure S14](#mmc1){ref-type="supplementary-material"}. Error bars correspond to one standard deviation.

The effective half-life (*t*~1/2~(eff)/h) of \[^89^Zr\]ZrDFO-azepin-trastuzumab was measured in mice by using a calibrated dosimeter ([Transparent Methods Figure S15](#mmc1){ref-type="supplementary-material"}). A value of *t*~1/2~(eff) = 45.7 ± 7.7 h was measured (*n* = 11; *R*^2^ ∼ 0.99) with an estimated biological half-life, *t*~1/2~(biol.) = 109.5 ± 18.4 h. No difference was observed between the normal and blocking groups. These data are consistent with previous reports on ^89^Zr-radiolabeled trastuzumab ([@bib7], [@bib16]).

After the final imaging time point, animals were euthanized and a biodistribution analysis was performed to obtain accurate quantification of the accumulation of ^89^Zr in different tissues ([Figure 11](#fig11){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"} and [Transparent Methods Figures S16--S19](#mmc1){ref-type="supplementary-material"}). Comparison of the biodistribution data between the normal and blocking groups showed a specific accumulation of radioactivity in the tumor (65.8% ± 14.2 %ID g^−1^ in the normal group versus 12.1% ± 4.1%ID g^−1^ in the blocking group, p value = 0.0006). With the exception of the activity retained in the blood pool (7.4% ± 1.0 %ID g^−1^ for the normal versus 4.8% ± 1.2 %ID g^−1^ for the blocking group \[p value = 0.003\]), no statistically significant differences were observed between radioactivity accumulation in the background tissues of the two groups of mice. Furthermore, a comparison of the tumor-to-tissue contrast ratios recorded from the biodistribution studies performed on the photoradiochemical product \[^89^Zr\]ZrDFO-azepin-trastuzumab and on \[^89^Zr\]ZrDFO-Nsucc-trastuzumab produced by a conventional conjugation route showed no statistically significant differences between the two radiotracers ([Transparent Methods Figure S20](#mmc1){ref-type="supplementary-material"}).([@bib16]) Collectively, the data from experiments performed *in vitro*, *in vivo,* and *ex vivo* indicate that the photoradiochemical route to ^89^Zr-radiolabeled trastuzumab yields a radiolabeled compound that is of equivalent quality to other ^89^Zr-mAbs produced via established methods.Figure 11Bar Chart Showing *Ex Vivo* Biodistribution Data (%ID/g) for the Uptake of \[^89^Zr\]ZrDFO-Azepin-Trastuzumab in Mice Bearing Subcutaneous SK-OV-3 TumorsData were recorded after the final imaging time point at 94 h post-injection. \*\*\*Student\'s t test p value \< 0.001. An equivalent plot using units of standardized uptake value is presented in [Figure S17](#mmc1){ref-type="supplementary-material"}. Data showing tumor-to-tissue contrast ratios are presented in [Figure S18](#mmc1){ref-type="supplementary-material"}. Error bars correspond to one standard deviation.Table 1*Ex Vivo* Biodistribution Data for \[^89^Zr\]ZrDFO-Azepin-Trastuzumab in Mice Bearing SK-OV-3 TumorsTissueNormal Group (*n* = 5)Blocking Group (*n* = 6)\[^89^Zr\]ZrDFO-Azepin-Trastuzumab (94 h)/%ID g^−1^ ± SD[a](#tblfn1){ref-type="table-fn"}Tumor-to-Tissue Contrast Ratio ± SD[b](#tblfn2){ref-type="table-fn"}\[^89^Zr\]ZrDFO-Azepin-Trastuzumab (94 h)/%ID g^−1^ ± SD[a](#tblfn1){ref-type="table-fn"}Tumour-to-Tissue Contrast Ratio ± SD[b](#tblfn2){ref-type="table-fn"}Blood7.36 ± 0.968.94 ± 2.254.79 ± 1.182.53 ± 1.05Tumor65.79 ± 14.191.0012.10 ± 4.061.00Heart2.58 ± 0.4925.51 ± 7.322.22 ± 0.285.45 ± 1.95Lungs4.22 ± 0.7515.57 ± 4.353.17 ± 0.603.82 ± 1.47Liver9.90 ± 1.446.64 ± 1.737.99 ± 2.561.51 ± 0.70Spleen5.28 ± 1.2412.45 ± 3.975.64 ± 1.482.14 ± 0.91Stomach0.79 ± 0.1583.03 ± 23.850.74 ± 0.1916.36 ± 6.95Pancreas1.39 ± 0.2847.27 ± 13.910.98 ± 0.1012.39 ± 4.37Kidney4.16 ± 0.5715.82 ± 4.033.35 ± 0.503.61 ± 1.33Small intestine1.28 ± 0.2851.30 ± 15.701.33 ± 0.289.13 ± 3.62Large intestine0.74 ± 0.2088.79 ± 30.950.79 ± 0.1715.29 ± 6.10Fat2.22 ± 1.2929.61 ± 18.310.78 ± 0.3215.49 ± 8.24Muscle0.82 ± 0.3079.84 ± 33.390.71 ± 0.1217.05 ± 6.39Bone9.86 ± 2.296.67 ± 2.125.85 ± 4.242.07 ± 1.65Skin4.51 ± 0.7314.58 ± 3.944.09 ± 0.862.96 ± 1.17[^3][^4]

Simultaneous Photoradiolabeling of Trastuzumab {#sec2.8}
----------------------------------------------

Previously, we demonstrated that the photoradiochemical approach was successful when radiolabeling either pre-purified mAbs or fully formulated samples (Herceptin) ([@bib31]). In addition to fast reaction and processing times, a one-pot procedure has the unique advantage of avoiding the need to isolate and characterize the conjugated intermediate antibodies. To illustrate the feasibility of the simultaneous photoradiochemical process, experiments were performed to produce \[^89^Zr\]ZrDFO-azepin-trastuzumab in a single step.

Reactions were established in which \[^89^Zr\]\[Zr(C~2~O~4~)~4~\]^4--^, compound **1**, and trastuzumab (at an initial chelate-to-mAb ratio of ∼29:1) were mixed in water and the pH adjusted to ∼8--9. Control reactions were performed in the absence of either the chelate (**1**) or the mAb. Mixtures were stirred gently at room temperature and irradiated using the LED source (365 or 395 nm) for 10 min. Note that in this case stirring appeared to be more important than in our previous experiments with ^68^Ga ([@bib31]). After irradiation, the reactions were quenched by the addition of diethylenetriamine pentaacetic acid (DTPA). Aliquots of the crude samples were retained, and a fraction was purified by SEC methods. Crude and purified samples were then analyzed by using radio-iTLC, analytical PD-10-SEC, and SEC-UHPLC methods ([Figure 12](#fig12){ref-type="fig"} and [Transparent Methods Table S3](#mmc1){ref-type="supplementary-material"}).Figure 12Characterization Data for the Simultaneous One-Pot Photoradiochemical Synthesis of \[^89^Zr\]ZrDFO-Azepin-Trastuzumab(A and B) (A) Radio-iTLC chromatograms showing control reactions in the absence of compound **1** (no chelate, green) or mAb (yellow), ^89^Zr-**1**^**+**^ before irradiation (purple), and the crude products after irradiation with 365 nm (black) and 395 nm (red). (B) Analytical PD-10-SEC elution profiles showing the \[^89^Zr\]\[ZrDTPA\]^--^ control (green, equivalent to the no chelate control confirming no non-specific binding of ^89^Zr^4+^ ions to the mAb), a control reaction without mAb (yellow), crude reaction mixtures after irradiation and DTPA quenching at 365 nm (black) and 395 nm (red), and the purified product (blue).(C) SEC-UHPLC chromatograms of the crude and purified product.

Analysis of the crude reaction mixtures also indicated that ∼72%--73% (*n* = 2, by analytical PD-10-SEC) and ∼67%--88% (*n* = 2, by SEC-UHPLC) of the ^89^Zr-radioactivity was associated with trastuzumab. Control reactions confirmed that the ^89^Zr radioactivity bound to trastuzumab specifically ([Figures 12](#fig12){ref-type="fig"}A and 12B, green and yellow traces). After purification, simultaneous photoradiolabeling gave \[^89^Zr\]ZrDFO-azepin-trastuzumab with a decay-corrected RCY of ∼76%, a RCP ∼97% (measured by SEC-UHPLC), and a molar activity of 0.41 MBq nmol^−1^ of protein (*n* = 2). Interestingly, both the 365- and 395-nm LED sources gave equivalent radiochemical conversions. Reactions were complete in \<10 min, and the entire process, from non-labeled trastuzumab to formulated \[^89^Zr\]ZrDFO-azepin-trastuzumab, was accomplished in \<15 min. With a higher intensity light source, it is conceivable that the photoradiochemical synthesis could be accomplished in a few seconds, which would mean that radiotracer production times are limited only by the time required for purification and quality control.

Comparison of the final RCYs measured between the two-step process and the simultaneous (one-step) process indicate that the photochemical conjugation efficiency increased from 3.5% to ∼76%. This result shows that the chemical efficiency of simultaneous photoradiolabeling is comparable to many of the most efficient thermally mediated methods, which typically display ∼60%--80% conjugation efficiency ([@bib15], [@bib16], [@bib17], [@bib34], [@bib39], [@bib40], [@bib41]). Under the conditions employed it is likely that the kinetics of metal ion complexation is equal to, or faster than, that of the photochemical conjugation step. Complexation of ^89^Zr^4+^ ions by the DFO-ArN~3~ chelate reduces the probability of intramolecular reactions between the nucleophilic hydroxamate groups and the photo-generated intermediates. Hence, pre-complexation increases the photochemical conjugation efficiency when compared with the free chelate (**1**). Notably, the photoradiochemical method is also suitable for use in fully automated radiochemical synthesis modules. Automated photoradiochemical synthesis has the potential to change the way in which radiolabeled mAbs, immunoglobulin fragments, and other proteins are produced in the clinic.

Conclusions {#sec2.9}
-----------

Experiments demonstrated that the photoradiolabeling methods are viable for the synthesis of radiolabeled antibodies for immuno-PET. In contrast to existing (thermochemical) technologies, photoradiochemistry allows for the rapid synthesis of \[^89^Zr\]ZrDFO-azepin-trastuzumab in high radiochemical yield and purity using a simultaneous, one-pot approach. Accessing radiolabeled proteins directly from the non-functionalized source eliminates the need to isolate and characterize a radiolabeling precursor (here DFO-azepin-trastuzumab). Our work illustrates the potential of applying photochemistry in radiopharmaceutical science. We continue to investigate the use of photoradiochemistry with different photoactivatable groups, chelates, and radionuclides for producing diagnostic and therapeutic radiopharmaceuticals based on proteins, peptides, small molecules, and nanoparticles.

Limitations of the Study {#sec2.10}
------------------------

Although photoradiochemistry offers an exciting alternative for the synthesis of radiolabeled proteins, and we have shown that photoradiochemistry can facilitate processes that are not achievable using standard thermochemical methods, some limitations exist. Namely, the success of the photoradiochemical reaction is dependent on the experimental geometry. The light-activation process was found to be highly efficient, but experimentally, the shape and focus point of the light beam, the photon flux, and the potential absorption or scattering from the reaction vessel or chemical components of the reaction mixture mean that care must be taken to achieve reproducible results. Similar to standard thermochemical methods, we have also discovered that the photochemical conjugation efficiency depends on the nature of the photoactive group, the chelate or complex, and also other factors including the protein, solvent composition, mixing efficiency, and concentration-dependent radiochemical kinetics ([@bib13]). Much work is required before photoradiochemical methods can be standardized.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S20, and Tables S1--S3
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